Aviva’s Sage Therapeutics SAGE Stock Holding History

Aviva’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-63,507	Closed	-$2.7M	–	1099
2021 Q4	$2.7M	Buy	63,507 +26,559	+72%	+$1.11M	0.01%	733
2021 Q3	$1.64M	Buy	+36,948	New	+$1.69M	0.01%	838
2021 Q2	–	Sell	-16,807	Closed	-$1.26M	–	961
2021 Q1	$1.26M	Buy	+16,807	New	+$1.38M	0.01%	770
2020 Q1	–	Sell	-12,485	Closed	-$901K	–	979
2019 Q4	$901K	Buy	+12,485	New	+$1.54M	0.01%	896

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Aviva's SAGE Position: Q1 2022 in Review

Aviva sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 63,507 shares — an estimated $2.7M sold.

Aviva first reported a position in SAGE in Q4 2019 and held it in 4 quarters. The position peaked at $2.7M in Q4 2021. 211 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

Aviva reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
Aviva sold 63,507 Sage Therapeutics shares in Q1 2022, an estimated $2.7M.
Aviva first reported a position in Sage Therapeutics in Q4 2019 and held it in 4 quarters.
Aviva's Sage Therapeutics position peaked at $2.7M in Q4 2021.
211 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Aviva's 13F filing for Q1 2022, filed 13 May 2022.